Updated: May 29, 2024

Published: July 2, 2020

A Novel Hanging Drop Organ-on-a-Chip System for Diabetes Drug Discovery

InSphero has a rich history of collaborating with researchers at ETH Zürich. The most recent example is a joint effort to develop and apply a novel Hanging Drop Organ-on-a-Chip System to study insulin release dynamics for diabetes drug discovery.

Our guest blogger, Melanie Johnson from the Technology Transfer Office at ETH Zürich, had a chance to interview Dr. Patrick Misun, Group Lead at the Bio Engineering Lab and ETH Zürich (currently Principal Scientist at Novartis Institutes for BioMedical Research), and Dr. Burcak Yesildag, Vice President of Islet Biology at InSphero, about their work, which was published in Advanced Biosystems. Here's the story.

Hanging Drop Organ-on-a-Chip System for Diabetes Drug Discovery

by Melanie Johnson

Dr. Burcak Yesildag and Dr. Patrick Misun talk about a new testing platform, the hanging drop organ-on-a-chip system, that will help diabetes researchers find new drugs and gain deeper insights into underlying biological mechanisms.

You are using human cells on your chip?

Patrick: That is correct. We build platforms for testing drugs outside the body under conditions that resemble those in the living organ as closely as possible. Our goal is to obtain physiologically meaningful and reproducible data. In this particular case, we studied the insulin secretion of pancreatic microtissues over time.

Your chip has an unusual design. It is open at the bottom. Drops are dangling from it. Why should researchers do secretion studies in hanging drops instead of properly enclosed chambers? The setup looks a bit shaky…

Patrick: The hanging drops have proven to provide an absolutely reliable and reproducible environment for drug testing on microtissues. We place single microtissues in individual drops, where they settle at the water-air interface at the bottom of the drop. We perfuse small volumes of liquid directly through these hanging drops to provide the tissue with nutrients and expose them to drugs. Flowing liquids inside hanging drops feature a unique flow pattern compared to flows in closed chambers. We take advantage of this specific flow pattern to obtain secretion profiles at high temporal resolution.

Akura™ hanging drop organ-on-a-chip

Akura™ Hanging Drop Organ-on-a-Chip System

Where does the sample tissue come from?

Patrick:  This is a question for my colleague Burcak from InSphero. For this project, we have an excellent collaboration in which ETH Zürich covers the engineering part for the organ-on-chip tests, and InSphero prepares the microtissues.

Burcak: Indeed, our complementary skills come in handy. At InSphero, we prepare pancreatic microtissues from donor organs. We obtain isolated human-donor islets, which are the micro-organs in the pancreas secreting hormones such as insulin, which regulates the blood sugar level in our body. We disassemble the islets, which come in different sizes and compositions, and reassemble them into standardized three-dimensional microtissues. The more regular the sample tissue is, the more reproducible will be the outcome of experiments with these tissues.

Are these fabricated microtissues still natural?

Burcak: Our pancreatic microtissues closely mimic the structure of the original human islets and preserve their natural response to various stimuli. When exposed to a high concentration of glucose, they display a first instantaneous burst of insulin secretion. Several minutes later, a somewhat less intense but well-sustained oscillatory release of insulin follows.  In the case of diabetes, these responses are impaired, and there are multiple strategies aiming at restoring healthy insulin secretion.

Researchers want to observe these details at a high temporal resolution so that they can better understand the mechanisms underlying diabetes and develop compounds for its treatment. The combination of robustly functioning islet microtissues with Patrick’s hanging-drop platform provides unprecedented temporal resolution as far as we know.

Last question: Is the organ-on-a-chip platform commercially available?

Burcak: The microtissues are readily available for collaborative projects with InSphero.

Patrick: Currently, we have working platform prototypes, and we are open to collaborations with academic and industrial partners to optimize our platform. Our prototypes enable us to perform very sensitive measurements of single islets. We hope this technological advancement will help diabetes researchers to find new drugs and to get deeper insights into islet biology. In the next step, we would like to increase the experimental throughput, as this is one of the key requirements for compound testing. Also, we are further decreasing the operational complexity with the goal of making the system available for researchers across different laboratories.

Want to learn more about the hanging drop organ-on-a-chip system?


This blog was originally published in ETH Zürich Industry News & Society News.

Cover image: Illustration of the hanging drop organ-on-a-chip system that enables researchers to maintain sample tissues in hanging drops by ETH Zürich. Reprinted with permission.

Read More

FDA Modernization Act 3.0
Blog

The FDA Modernization Act 3.0: Paving the Way for e New Era in Drug Development or a Gentle Nudge?

In a significant step toward making drug development more patient-centric, the FDA Modernization Act 3.0 was introduced as a major piece of forward-looking legislation in February 2024. For stakeholders across the biopharmaceutical industry, including companies like InSphero that specialize in complex in vitro models, this legislation presents both promising opportunities and new challenges. Will it change things?

Read More »
antisense oligonucleotides
Blog

Understanding the DILI Risks of Antisense Oligonucleotides and the Value of Predictive In Vitro Testing

Antisense oligonucleotides (ASOs) offer therapeutic avenues for diseases that are currently unmet by alternative therapeutic modalities. However, the development of therapeutic ASOs is often hampered by hepatotoxicity. In this blog, we explore why 3D human liver microtissues are becoming an indispensable tool for de-risking ASO drug candidates and for reducing attrition in late-stage drug development. 

Read More »
Testing Drug-induced Mitochondrial Toxicity in 3D InSight™ Human Liver Microtissues
Blog

Testing Drug-induced Mitochondrial Toxicity in 3D InSight™ Human Liver Microtissues

Toxicological studies show that drugs can alter mitochondrial functions, potentially resulting in a deleterious range of toxic reactions from the induction of micro- and macrovesicular steatosis to lactic acidosis. These clinical manifestations are the consequence of drugs interfering with four main mitochondrial functions or constituents: aerobic respiration, beta-oxidation, and mitochondrial DNA homeostasis.

Read More »
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource